Search Results - therapeutics




31 Results Sort By:
Topical treatment with TGFbeta3 to facilitate skin and corneal wound healing in diabetic patients
Topical Treatment with TGFb3 to Facilitate Skin and Corneal Wound Healing in Diabetic Patients WSU Tech#: 14-1207 Technology Summary: TGFb3 has been implicated in the reduction of scar formation in wound healing. Renovo Group PLC, is a European based biopharmaceutical company developing drugs to reduce scaring, improve wound healing and enhance...
Published: 2/10/2017   |   Inventor(s): Fu-Shin Yu
Keywords(s):  
Category(s): Medical, Biologicals, Biomedical, Drug Discovery, Metabolic disorders, Protein/peptides, Therapeutics
New Method of Treating B-Cell Cancers
Background Non-Hodgkin’s Lymphomas (NHL) is one of the most frequent malignant lymphomas found in both children and adults with over 70,000 cases a year in the US. B-cell lymphomas make up nearly 85% of NHL cases. The most common type of treatment is an aggressive form of chemotherapy with or without the addition of newer antibody based drug ...
Published: 1/19/2017   |   Inventor(s): Ashok Bhagwat
Keywords(s):  
Category(s): Life Science, Oncology, Pharmaceuticals, Therapeutics
Topical IL-1Ra (anakinra) in the form of gel to treat persistent diabetic skin and corneal wounds
BackgroundAnakinra (aka. Kineret) is a recombinant human IL-1Ra that was developed by Amgen. It is currently used to treat moderately to severely active rheumatoid arthritis, but also treats neonatal-onset multisystem inflammatory disease (NOMID). Anakinra is given as an IV dose and the drug is no longer under patent. The properties of Anakinra a...
Published: 5/25/2016   |   Inventor(s): Fu-Shin Yu
Keywords(s):  
Category(s): Biologicals, Drug Discovery, Pharmaceuticals, Therapeutics
Antibacterial activity of natural compounds and their synthetic analogue: A potential new antibiotic with potent activity against multiple drug resistant bacterial pathogens
Our researchers have developed novel compounds that are potential antibiotics useful for treatment against the deadly bacteria MRSA (methicillin-resistant Staphylococcus aureus), VRE (vancomycin-resistant Enterococcus faecium), and several other well-known common infectious agents.Background & Unmet Need:Before antibiotics became available in t...
Published: 5/12/2015   |   Inventor(s): Fazlul Sarkar, Hossein Salimnia, Subhash Padhye, Bernhard Biersack
Keywords(s): Antibiotics, Disease, Analog or Analogue, Anti-infective, Anti-microbial
Category(s): Biologicals, Diseases, Infectious disease, Life Science, Therapeutics
IMAGING TUMORS USING PHOSPHOAMIDATE DERIVATIVES OF FAU
TechnologyPhosphoramidate derivatives of a furanosylurical analog (FAU-PA) have been developed which can effectively deliver intracellular FAU monophosphate. This results in improved formation of nucleoside triphosphates and higher incorporation into DNA and can be used for imaging and to treat cancers. When labeled with F-18 it may function as a P...
Published: 8/22/2014   |   Inventor(s): Anthony Shields, Jiri Zemlicka, Sridhar Nimmagadda
Keywords(s): Anti-cancer, Compound, Imaging
Category(s): Imaging, Life Science, Oncology, Therapeutics
67DHB Grapefruit Inhibitor
The invention comprises a composition and methods for inhibiting cytochrome P450 enzyme activity and, in particular, inhibiting the activity of the cytochrome P450 3A sub-family of enzymes, specifically, CYP3A4. It is believed that 6',7'-dihydroxybergamottin, a furanocoumarin, is the compound primarily responsible for the inhibitory effects of gra...
Published: 6/10/2013   |   Inventor(s): Patrick Woster, David Edwards
Keywords(s):  
Category(s): Therapeutics, Life Science, Oncology
Nanoparticle Method to Stabilize Suspension-Based pMDI HFA Formulations
Novel nanoparticle-based drug compositions and methods that improve and expand therapeutic drug delivery to the lungs through pressurized meter-dose inhalers (pMDIs). A large variety of approaches have been developed at WSU aimed at improving the aerosol characteristics and expanding the range of target species deliverable. These improved formulati...
Published: 4/23/2013   |   Inventor(s): Sandro da Rocha, Libo Wu
Keywords(s): Asthma, Pharmaceuticals, Formulation, Drug Delivery, Nanomaterials
Category(s): Drug Delivery, Life Science, Nano-based, Therapeutics
Dual action nanocarrier combining CXCR4 antagonist and polyplex gene delivery for treatment of metastatic cancer and other diseases
Novel bio-reducible polymer compositions which combine the ability to act as a CXCR4 antagonist and simultaneously provide enhanced gene delivery through the formation of inert nanocarrier polyplexes have been developed. As would be expected for biodegradable polymers, the cytotoxicity of these nanocarrier compositions are very low with measured IC...
Published: 9/10/2012   |   Inventor(s): David Oupicky, Jing Li
Keywords(s): Cancer, Cancer Therapies, Compound, Drug Delivery, Formulation, Nanomaterials, Pharmaceuticals, Therapeutics, Drug Target, Imaging
Category(s): Drug Delivery, Gene Therapy, Therapeutics, Life Science, Oncology, Nano-based, Metabolic disorders, Biologicals
Drug-Dendrimer Nanoparticles for Targeted Treatment of Neuroinflammation
Highly effective dendrimer-drug based compositions and methods for treatment have been developed that target neuroinflammation both in the brain and the retina upon intravenous administration. The nanodevices overcome the blood-brain barrier (BBB) and deliver drugs to target cells (activated microglia and astrocytes) producing dramatic therapeutic ...
Published: 8/2/2012   |   Inventor(s): Rangaramanujam Kannan, Raymond Iezzi, Bharath Rajaguru, Sujatha Kannan
Keywords(s): Alzheimer's Disease, Compound, Disease, Drug Delivery, Imaging, Nanomaterials, Nanotechnology, Neural Probes, Neuro-disorders, Parkinson's, Pharmaceuticals, Therapeutics
Category(s): Drug Delivery, Therapeutics, Diseases, Life Science, Nano-based, Vision, Imaging, Neurological disorders, Dendrimer
Repurposing AKT Inhibitors for the Treatment of Protein Misfolding and Protein Trafficking Diseases
Wayne State University researchers have demonstrated that inhibition of pro-survival kinase, AKT, using the transgene, Trb3, expressed in oligodendrocytes, leads to less brain white matter than controls. Moreover, Trb3 introduction into an animal model of the human disease, Pelizaeus Merzbacher disease (PMD) leads to less myelin thickness and ...
Published: 6/22/2010   |   Inventor(s): Alexander Gow, Cherie Southwood
Keywords(s): Alzheimer's Disease, Anti-cancer, Neuro-disorders, Parkinson's
Category(s): Biotechnology, Life Science, Neurological disorders, Oncology, Therapeutics
1 2 3 4